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of radiation sensitivity. A subset of these candidate 
molecules could be validated having an impact in clinical 
outcome of radiation therapy treated HNSCC patients.  
 
Conclusion: Our study demonstrates that multi-level 
radiation systems biology allows gaining deeper insights into 
chief mechanisms of radiation sensitivity, thereby paving the 
way for targeted individualised therapy approaches in 
radiation oncology. 
 
Debate: This house believes that progress in the treatment 
of locally advanced NSCLC will come from:  
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A large proportion of non-small cell lung cancer (NSCLC) 
patients are diagnosed with locally advanced (stage III) 
disease. For this patient group the treatment of choice is 
definitive concurrent chemoradiation (CCRT). CCRT results in 
an improved overall survival (OS) compared to sequential 
chemoradiotherapy or radiotherapy alone because of 
improved locoregional control. However 2-year OS rates of 
30-35% are still poor because many patients develop 
locoregional failures (about 30%) and distant metastases 
(about 40%)1. Currently locally advanced NSCLC patients 
selected for CCRT have FDG-PET scanning and imaging of the 
brain (MRI or CT scan). Despite this brain imaging with the 
present chemotherapy regimens used we are faced with the 
problem of brain metastases in about 10% of the patients 
within 1 year after chemoradiation.  
In several chemoradiation studies it was reported that the 
Gross Tumor Volume is correlated with OS. This is rational 
since the tumor volume represents the number of clonogenic 
tumor cells that needs to be eradicated. To improve 
locoregional control the dose prescription could be escalated 
taking into account the individual Gross Tumor Volumes and 
tolerances using image guided adaptive Intensity Modulated 
Radiotherapy (IMRT). However there are radiation oncologists 
who challenge the usefulness of RT dose escalation and 
intensification in patients with stage III NSCLC. The outcome 
of a randomized phase III trial, RTOG 06171, revealed that 
NSCLC patients within the 74 Gy arm given in 7.5 weeks had 
worse local control and significantly worse overall survival as 
compared to the patients treated to 60 Gy arm in 6 weeks2. 
Patients in all study arms received two additional cycles of 
consolidation chemotherapy ± cetuximab. So the obvious 
question is: How do we continue?  
Dose escalation with prolonged overall treatment time in 
NSCLC has previously been proven disappointing because of 
accelerated repopulation3.In an individual patient data meta-
analysis in patients with non-metastatic lung cancer, which 
included trials comparing modified radiotherapy with 
conventional radiotherapy, a significant OS benefit from 
accelerated or hyperfractionated radiotherapy was reported4. 
Another issue is the use of consolidation chemotherapy after 
concurrent chemoradiation. In the RTOG 0617 trial the 
increase in mortality started < 3 months after randomization 
during the period of consolidation paclitaxel-carboplatin 
chemotherapy. Generally taxanes given after RT increases 
toxicity and the combination of high dose to the heart and 
consolidation taxane-based chemotherapy might have caused 
toxic deaths and biased the outcome. RT dose intensification 
while using modern image guided adaptive IMRT and 
accelerated schemes is an important area of ongoing clinical 
research and should not be discontinued.  
In Stereotactic Ablative Body Radiotherapy (SABR) much 
higher biologically equivalent doses are delivered compared 
to conventionally fractionated RT (typically EQD2 of 70-85 
Gy), and has generated outstanding tumor control in early 
stage NSCLC. For SABR a significant dose–response 
relationship was observed for prescription EQD2 of 105 Gy or 
more (2-year LC 96%) or of less than 105 Gy (2-year LC 85%)5. 
Tumor size and overall treatment time were also important 
factors influencing outcome.  
The tumor control probability of SBRT (small tumor volume) 
and conventionally fractionated chemoradiation (large tumor 
volume) were successfully described in a single model6 
suggesting that a dose-response relation in NSCLC does exist.  
Recently there is a growing interest in genetic profiles that 
predict a patient’s response to radiotherapy, because severe 
toxicity in a minority of patients limits the doses that can be 
safely given to the majority. Recent progress in genotyping 
raises the possibility of genome-wide studies. If we know the 
normal tissue reactions to radiotherapy by genotype we will 
really be able to tailor the individual radiation dose.  
In conclusion: Besides the unsolved problem of the 
occurrence of distant metastases there is room for 
improvement of locoregional control in locally advanced 
NSCLC patients treated with chemoradiation. In the era of 
personalized treatment, radiotherapy dose intensification 
using image guided adaptive IMRT could be directed towards 
individual tumor volumes and tolerances. RT dose 
intensification while using accelerated schemes is an 
important area of ongoing clinical research  
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About one third of patients with non-small cell lung cancer 
(NSCLC) present with locoregional disease extension in either 
the mediastinum (T4) or the mediastinal lymph nodes (N2/3). 
Apart from a fraction in which resection after induction 
therapy is sometimes considered, selected patients with 
stage 3 are candidate for a so-called definitive 
radiochemotherapy, administered either sequentially or 
concomitantly. Despite staging with PET-CT scan and 
endosonographic mapping of mediastinal lymph nodes and 
notwithstanding a patient selection for this radical 
treatment, the outcome in stage 3 is nevertheless moderate 
with a median survival of 2 years [1]. Progression occurs after 
a median of 10 months and is due to local relapse or distant 
metastasis in 30 and 45% of cases, respectively. Any advance 
in the outcome in stage 3 NSCLC will hence depend on 
improvements in systemic therapy directed at distant 
metastasis. The past 10 years have seen important changes in 
the paradigm of treatment in selected patients with 
advanced NSCLC, in whom platinum-based doublet 
chemotherapy used to be the standard of care. The discovery 
of drugable genomic alterations has introduced precision 
medicine in oncology. Patients whose NSCLC harbour either 
an activating EGFR mutation, EML-ALK translocation or ROS1 
amplification are now routinely treated with oral small 
molecule kinase inhibitors of the 1st, 2nd and 3rd generation 
instead of chemotherapy, with a significant improvement in 
outcome and a substantial impact on quality of life. Similar, 
although less pronounced effects have been observed when 
adding monoclonal antibodies directed at targets associated 
with angiogenesis or cell growth to the chemotherapy 
backbone. Unfortunately, the incorporation of these 
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‘targeted’ agents in current radiochemotherapy, either given 
concomitantly or as consolidation, was not successful with 
even detrimental results due to an increased toxicity and 
mortality. A lack of adequate patient selection based on the 
presence of the target biomarker may have contributed to 
these failures, as subgroup analyses suggest a benefit in 
target expressing patients. Trials are ongoing specifically 
addressing patients with stage 3 NSCLC and either an 
activating EGFR mutation or EML-ALK translocation. 2015 has 
seen the rapid implementation of immunotherapy in NSCLC 
treatment, with several monoclonal antibodies inhibiting 
checkpoint molecules showing superior outcome over 2nd line 
docetaxel. These agents will now advance in earlier stages 
and phase 3 trials with a consolidation strategy are ongoing. 
Controversial issues remain patient selection based on 
predictive biomarker expression, the combination of 
different checkpoint inhibitors and the risk of synergistic late 
pulmonary toxicity, when added to definitive thoracic 
radiotherapy. Although it is tempting to early implement 
promising new drugs in stage 3 treatment, caution should 
guide its sequencing within the radiochemotherapy 
backbone. Window of opportunity trials with induction 
treatment in biomarker selected patients will allow to 
explore the single agent activity and minimize the risk of 
additional toxicity.  
1: Bradley JD et al. Lancet Oncol 2015; 16: 187–99 
 
Symposium: Active surveillance for low risk prostate 
cancer: to treat or not to treat?  
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Prostate cancer could be considered as insignificant or 
indolent (IPCa) when its presence does not bring about any 
risk for the life of the patient. If we start with this idea it is 
easy to understand that this situation is very difficult to 
predict since it depends on many variables of each patient, 
among which the life expectancy of the patient is one of the 
most important; therefore, it would seem to be a more 
theoretical question than practical, if it were not because it 
reflects an emerged reality by finding that up to 31% of the 
prostate carcinomas detected by high PSA serum levels, 
through study of the prostatectomy specimen, there were 
only small nodules of carcinoma that could have remained 
totally localized (latent) during the entire life of the patient, 
therefore they could have been treated with watchful 
waiting. It is clear that all of this supposition is a speculative 
exercise and only comes from indirect suppositions of the 
probable biology of a carcinoma node by its pathological 
characteristics. This fact explains that there are diverse 
definitions of IPCa in the radical prostatectomy specimens, 
although all coincide in requiring a small volume of tumor (< 
5cc, although there is an author that accepts < 1cc), absence 
of aggressive Gleason patterns (no 4 or 5 patterns or Gleason 
score <7) and the majority also require, for a tumor to be 
accepted as indolent, to be a confined organ tumour with 
negative margins. In accordance with these criteria, the 
prevalence of IPCa varies between 2.3% and 31%, with an 
average of 18.3%. However, this uniformity of criteria is not 
the same at the time of determining the pre-operative model 
to predict IPCa, possibly because all the studies that try to 
correlate the extension of the prostate cancer in the biopsy 
with the volume in the prostatectomy specimen show that 
this correlation is very weak; and therefore, although all the 
needle biopsy criteria for defining an IPCa require the 
absence of an aggressive Gleason pattern (pattern 4 and 5 or 
Gleason score ≤ 7) would vary as regards the extension of the 
tumor in the cores (< 3 core with no core >50% of the 
surface, only one positive core < 3mm, 1% of all the cores, no 
core > 10% of the surface) and the inclusion between the 
criteria of the PSAD (PSA density). With all this variability the 
presumption of a possible IPCa in the radical prostatectomy 
specimen of the different authors has a sensitivity of 23% to 
83.9% (average 53.2%) and a specificity of 61.9% to 99% 
(average 89.1%). Maybe it will help us to better identification 
of very low aggressive P.Ca patients the recent redefinition 
of Gleason patterns and the proposed grouping of prognostic 
grades. A new International Society Urogenital Pathology 
revision in November 2014 defined the current criteria with a 
precise definition of Gleason pattern 3 as small glands with 
variation in size and shape infiltrating amongst non neoplasic 
glands and Gleason pattern 4 according four different aspects 
as all cribriform growth (some of them previously considered 
as pattern 3), fused glands, ill defined glands and 
glomeruloid glands. But with the intention to improve the 
correlation with the clinical parameters a new grading system 
was. This new system follows the accepted the new Gleason 
patterns grouping them in five prognostic groups: Group 1 
(Gleason 3+3), Group 2 (Gleason 3+4), Group 3 (Gleason 4+3), 
Group 4 (Gleason 4+4) and Group 5 (score Gleason 9 and 10). 
According this new arrangement an excellent correlation with 
the risk of biochemical recurrence we can obtain in needle 
biopsy and radical prostatectomy specimens. 
Prostate cancer is considered insignificant (IPCa) when its 
presence does not bring any vital risk. IPCa in the radical 
prostatectomy is a small (< 5cc,), No Gleason 4 or 5, organ 
confined, negative margins. The average prevalence is 18.3%. 
The pre-operative model to predict IPCa is difficult. In the 
IPCa identification can help the new ISUP Gleason revision, 
pattern 3 small glands with variation in size and shape and 
Gleason pattern 4 according four different aspects as all 
cribriform growth, fused, ill defined and glomeruloid glands. 
A new system was accepted grouping them in five prognostic 
groups: 1 (3+3), 2 (3+4), 3 (4+3), 4 (Gs8) 5 (Gs9,10), with 
excellent clinical correlation .  
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T2-weighted MRI (T2w) typically shows a prostate cancer as a 
low signal-intensity area among the high signal-intensity 
normal peripheral zone tissue background. In the transition 
zone, prostate cancer has an equally low signal-intensity, 
although contrasting less well with the surrounding 
heterogeneous signal-intensity of glandular and stromal 
hypertrophy. It has been shown that the observed signal 
intensity inversely correlates to some extent with the 
aggressiveness of the cancer (lowest signal intensities in 
higher grade cancers). The sensitivity of T2w imaging for 
prostate cancer (of any Gleason grade) is quite high (up to 
85%), but with a low specificity (about 55%) due to many 
false positive calls. Therefore, functional imaging tools are 
required to improve the overall diagnostic accuracy.  
Diffusion-weighted MRI (DWI) is currently the most important 
functional technique in addition to T2w MRI. Its mechanism is 
based on the inhibition of spontaneous water diffusion in 
tumor areas, due to both increased cellularity (more 
hydrophobic cell membranes inhibiting water diffusion) and 
destruction of fluid-rich acini and ductules. Prostate cancers 
can hence be detected as areas of decreased signal-intensity 
on apparent diffusion coefficient (ADC) maps or as increased 
signal-intensity on high b-value images. It is more than 
noteworthy that a quite robust inverse correlation exists 
between ADC-values and tumor aggressiveness (lowest ADC-
value in higher grade cancers).  
Dynamic contrast-enhanced MRI (DCE) measures the amount 
and characteristics of tumoral neoangiogenesis. After an 
intravenous bolus injection of gadolinium-containing contrast 
media, prostate cancers tend to enhance earlier, more 
rapidly and with a more pronounced de-enhancement (wash-
out) than benign or normal tissue. DCE greatly helps 
detecting cancers in the peripheral zone, but suffers from 
false positive calls in the transition zone due to similar 
enhancement characteristics in glandular hypertrophy.  
Magnetic resonance spectroscopic imaging (MRSI) is a more 
advanced tool that currently is mainly performed in expert 
centers and in clinical trials. It is based on measurement of 
the relative concentrations of citrate and choline, markers of 
benign and malignant tissue, respectively. MRSI adds 
